# Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Source: https://onco.cc/trials/nct05833724/  
OnCo record `nct05833724` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tucidinostat (chidamide) in peripheral T-cell lymphomas, run by Great Novel Therapeutics Biotech & Medicals Corporation, now recruiting.

## Summary

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) is a phase 2 interventional study registered as NCT05833724 by Great Novel Therapeutics Biotech & Medicals Corporation, with 33 participants planned, started 2024-10-18 and due to reach its primary completion in 2027-06. Interventions recorded: Chidamide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05833724
- Phase: 2
- Setting: A Phase II, Open-label, Single-arm, Multicenter Study of Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
- Sponsor: Great Novel Therapeutics Biotech & Medicals Corporation
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT05833724: https://clinicaltrials.gov/study/NCT05833724

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- drugs: [Tucidinostat (chidamide)](https://onco.cc/drugs/tucidinostat/)

---
JSON: https://onco.cc/api/v1/entities/nct05833724.json